We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Bristol-Myers Squibb has announced positive results from its trial into the efficacy of combination therapy with Opdivo (nivolumab) and Yervoy (ipilimumab), compared with either drug as a monotherapy, for patients with advanced melanoma.